Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Nonrandomized Multicenter Study of the Impact of Radiochemotherapy (65 Gy + Cisplatin + 5FU) Combined With Cetuximab in Patients Presenting With Locally Advanced Anal Cancer

NCT00955240 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT00955240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00955240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Nonrandomized Multicenter Study of the Impact of Radiochemotherapy (65 Gy + Cisplatin + 5FU) Combined With Cetuximab in Patients Presenting With Locally Advanced Anal Cancer
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2009
Completion date
November 26, 2010
Enrollment
16 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer